Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 5358 | 7.27 |
09:36 ET | 400 | 7.125 |
09:41 ET | 847 | 7 |
09:43 ET | 300 | 7 |
09:45 ET | 505 | 6.9501 |
09:48 ET | 390 | 7.015 |
09:50 ET | 1242 | 7 |
09:52 ET | 436 | 6.9875 |
09:54 ET | 2100 | 6.9999 |
09:56 ET | 600 | 7.04 |
09:57 ET | 145 | 7.02 |
10:01 ET | 100 | 7.03 |
10:03 ET | 499 | 7.0462 |
10:06 ET | 100 | 7.04 |
10:08 ET | 2548 | 7.07 |
10:15 ET | 141 | 7.0665 |
10:21 ET | 456 | 7.07 |
10:24 ET | 1711 | 7.035 |
10:26 ET | 517 | 7 |
10:28 ET | 100 | 6.98 |
10:30 ET | 382 | 6.981 |
10:32 ET | 600 | 7.01 |
10:33 ET | 2877 | 7.01 |
10:37 ET | 498 | 6.96 |
10:39 ET | 100 | 6.97 |
10:46 ET | 716 | 6.943 |
10:50 ET | 4614 | 6.96 |
10:53 ET | 100 | 6.95 |
10:55 ET | 200 | 6.945 |
10:57 ET | 500 | 6.9301 |
11:00 ET | 200 | 6.95 |
11:02 ET | 600 | 6.925 |
11:04 ET | 295 | 6.9 |
11:06 ET | 1286 | 6.9001 |
11:08 ET | 1004 | 6.93 |
11:11 ET | 12079 | 6.84 |
11:13 ET | 500 | 6.85 |
11:15 ET | 573 | 6.85 |
11:18 ET | 100 | 6.81 |
11:20 ET | 600 | 6.88 |
11:24 ET | 348 | 6.85 |
11:27 ET | 100 | 6.85 |
11:29 ET | 300 | 6.8499 |
11:31 ET | 400 | 6.85 |
11:33 ET | 1517 | 6.83 |
11:38 ET | 3201 | 6.93 |
11:40 ET | 2200 | 6.92 |
11:44 ET | 150 | 6.9495 |
11:45 ET | 100 | 6.96 |
11:47 ET | 150 | 6.94 |
11:49 ET | 400 | 6.96 |
11:54 ET | 275 | 6.92 |
11:56 ET | 100 | 6.97 |
11:58 ET | 100 | 6.97 |
12:02 ET | 923 | 6.91 |
12:05 ET | 100 | 6.905 |
12:09 ET | 2698 | 6.91 |
12:12 ET | 1220 | 6.94 |
12:14 ET | 380 | 6.9351 |
12:16 ET | 100 | 6.8801 |
12:18 ET | 100 | 6.91 |
12:20 ET | 500 | 6.8914 |
12:27 ET | 820 | 6.88 |
12:30 ET | 1045 | 6.915 |
12:32 ET | 2200 | 6.9395 |
12:34 ET | 100 | 6.89 |
12:38 ET | 4445 | 6.84 |
12:39 ET | 100 | 6.81 |
12:41 ET | 650 | 6.825 |
12:43 ET | 398 | 6.8 |
12:45 ET | 2264 | 6.7501 |
12:48 ET | 400 | 6.75 |
12:50 ET | 3697 | 6.835 |
12:52 ET | 2293 | 6.88 |
12:54 ET | 990 | 6.85 |
12:56 ET | 139 | 6.845 |
12:57 ET | 100 | 6.8 |
12:59 ET | 4000 | 6.8532 |
01:01 ET | 700 | 6.82 |
01:03 ET | 822 | 6.87 |
01:10 ET | 900 | 6.85 |
01:15 ET | 600 | 6.85 |
01:19 ET | 179 | 6.85 |
01:21 ET | 100 | 6.845 |
01:28 ET | 1399 | 6.92 |
01:30 ET | 100 | 6.905 |
01:32 ET | 500 | 6.9064 |
01:37 ET | 900 | 6.9024 |
01:39 ET | 381 | 6.8801 |
01:42 ET | 350 | 6.9041 |
01:48 ET | 200 | 6.9 |
01:53 ET | 600 | 6.9 |
01:55 ET | 557 | 6.9 |
01:57 ET | 100 | 6.85 |
02:00 ET | 466 | 6.9 |
02:06 ET | 101 | 6.85 |
02:08 ET | 100 | 6.86 |
02:09 ET | 200 | 6.86 |
02:15 ET | 200 | 6.875 |
02:18 ET | 300 | 6.89 |
02:20 ET | 200 | 6.88 |
02:22 ET | 1000 | 6.89 |
02:24 ET | 100 | 6.88 |
02:26 ET | 319 | 6.88 |
02:27 ET | 100 | 6.87 |
02:38 ET | 1000 | 6.885 |
02:40 ET | 100 | 6.87 |
02:42 ET | 300 | 6.886 |
02:47 ET | 2778 | 6.86 |
02:51 ET | 600 | 6.855 |
02:54 ET | 300 | 6.875 |
02:58 ET | 1000 | 6.86 |
03:00 ET | 900 | 6.8608 |
03:03 ET | 800 | 6.86 |
03:05 ET | 638 | 6.87 |
03:09 ET | 1600 | 6.91 |
03:14 ET | 700 | 6.9 |
03:16 ET | 200 | 6.95 |
03:18 ET | 100 | 6.92 |
03:20 ET | 100 | 6.95 |
03:21 ET | 400 | 6.95 |
03:25 ET | 1634 | 6.97 |
03:30 ET | 100 | 6.97 |
03:32 ET | 200 | 6.98 |
03:34 ET | 800 | 6.95 |
03:36 ET | 200 | 6.95 |
03:39 ET | 100 | 6.95 |
03:41 ET | 422 | 7 |
03:43 ET | 4071 | 6.98 |
03:48 ET | 100 | 6.9573 |
03:50 ET | 3425 | 6.91 |
03:56 ET | 619 | 6.99 |
03:57 ET | 650 | 6.95 |
03:59 ET | 17602 | 6.97 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 207.6M | -4.1x | --- |
Greenwich Lifesciences Inc | 215.2M | -23.2x | --- |
Fractyl Health Inc | 212.7M | -2.6x | --- |
Rezolute Inc | 212.2M | -3.6x | --- |
ATAI Life Sciences NV | 212.6M | -5.3x | --- |
ESSA Pharma Inc | 222.7M | -8.0x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.6M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 2,562.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.